
FULC Stock Forecast & Price Target
FULC Analyst Ratings
Bulls say
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company with a promising product candidate, Pociredir, in development for sickle cell disease (SCD). However, the recent discontinuation of the SCD program due to FDA feedback raises concerns about the company's pipeline and its ability to create value in the near-term. With limited visibility and the need for cost-cutting and strategic alternatives, a cautious stance is warranted and we are downgrading our rating to Market Perform with a $4 price target.
Bears say
Fulcrum Therapeutics is facing multiple risks related to its clinical, regulatory, and financial performance, which could negatively impact the stock. The discontinuation of its lead product candidate, Pociredir, for the treatment of sickle cell disease due to safety concerns raised by the FDA is a major setback for the company. With a projected mid-2027 cash balance of $234 million and a lack of strategic alternatives in sight, the stock's price target is cut to $3 from $23. Additionally, Fulcrum might require additional capital, posing a risk to achieving its price target.
This aggregate rating is based on analysts' research of Fulcrum Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
FULC Analyst Forecast & Price Prediction
Start investing in FULC
Order type
Buy in
Order amount
Est. shares
0 shares